Data from Moderna and Merck skin cancer Phase 2 trials shows an “extremely strong result” for a personalised cancer vaccine. Photo: Shutterstock Images
Data from Moderna and Merck skin cancer Phase 2 trials shows an “extremely strong result” for a personalised cancer vaccine. Photo: Shutterstock Images